Forebyggelse af tromboemboliske komplikationer hos medicinske patienter med høj risiko for tromboemboliske komplikationer på grund af immobilisering under akut sygdom I et randomiseret, dobbeltblindt klinisk forsøg blev 839 patienter behandlet med fondaparinux 2, 5 mg en gang daglig i 6- 14 dag.
Prevention of Venous Thromboembolic Events (VTE) in medical patients who are at high risk for thromboembolic complications due to restricted mobility during acute illness In a randomised double-blind clinical trial, 839 patients were treated with fondaparinux 2.5 mg once daily or placebo for 6 to 14 days.